Lifileucel induces a durable response in heavily pretreated mucosal melanoma Presented ByDr Evidio Domingo-Musibay, Masonic Cancer Center, USA TrialPhase 2, C-144-01 ConferenceESMO 2023 19 December, 2023 11:15
Darovasertib/crizotinib combination: a potential first-line therapy in metastatic uveal melanoma Presented ByDr Meridith McKean, Tennessee Oncology, USA ConferenceESMO 2023 19 December, 2023 11:06
Improved AI tool shows high sensitivity rates in skin cancer detection Presented ByDr Kashini Andrew, University Hospitals Birmingham NHS Foundation Trust, UK ConferenceEADV 2023 28 November, 2023 09:46
Dermoscopy training combined with AI significantly improves skin cancer detection Presented ByDr Christian Dorado Cortez, University Hospital of Saint-Etienne, France ConferenceEADV 2024 28 November, 2023 09:43
Response-directed treatment personalisation in stage III melanoma Presented ByDr Irene Reijers, Netherlands Cancer Institute, the Netherlands TrialPhase 2, OpACIN-neo, PRADO ConferenceASCO 2023 2 August, 2023 09:30
Prognostic and predictive biomarkers in patients with resected stage IIB/C melanoma Presented ByProf. Georgina Long, University of Sydney, Australia TrialPhase 3, CheckMate76K ConferenceASCO 2023 2 August, 2023 09:27
The role of surgeons in stage I–II melanoma Presented ByDr Dirk Grünhagen, Erasmus MC, the Netherlands ConferenceDDD 2023 10 May, 2023 13:26
Melanoma: Surveillance and follow-up Presented ByDr Remco van Doorn, Leiden University Medical Center, the Netherlands ConferenceDDD 2023 10 May, 2023 13:19
OCT non-inferior to biopsy in basal cell carcinoma Presented ByDr Tom Wolswijk , Maastricht UMC, the Netherlands ConferenceDDD 2023 10 May, 2023 12:42
Treatment with tumour-infiltrating lymphocytes for advanced melanoma outperforms ipilimumab Presented ByProf. John Haanen, Netherlands Cancer Institute, the Netherlands ConferenceESMO 2022 16 November, 2022 18:29
Neoadjuvant pembrolizumab outperforms adjuvant pembrolizumab in resectable stage III–IV melanomas Presented ByDr Sapna Patel, MD Anderson Cancer Center, TX, USA TrialPhase 2, SWOG S1808 ConferenceESMO 2022 16 November, 2022 18:26
Survival-benefit of neoadjuvant T-VEC maintained over 5 years of follow-up Presented ByProf. Reinhard Dummer, University of Zürich, Switzerland TrialT-VEC ConferenceESMO 2022 16 November, 2022 18:24
Baseline ctDNA predicts survival in resected stage III–IV melanoma Presented ByProf. Georgina Long, University of Sydney, Australia TrialPhase 3, CheckMate 915 ConferenceESMO 2022 16 November, 2022 18:21
Markedly lower skin cancer risk in vitiligo patients Presented ByDr John Ferguson, St John’s Institute of Dermatology, UK ConferenceEADV 2022 5 November, 2022 10:47
First results on distant metastasis-free survival in stage II melanoma Presented ByProf. Georgina Long, The University of Sydney, Australia TrialPhase 3, KEYNOTE-716 ConferenceASCO 2022 5 August, 2022 13:54
Higher response rates for concurrent triple therapy versus sequential therapy in melanoma Presented ByProf. Georgina Long, The University of Sydney, Australia TrialPhase 2, NeoTrio ConferenceASCO 2022 5 August, 2022 13:50
Adjunctive reflective confocal microscopy can curb unnecessary excision for suspected melanoma JournalJAMA Dermatology 10 June, 2022 20:27
Kids with solid-organ transplants also at risk for keratinocyte carcinoma JournalJAMA Dermatology 10 June, 2022 17:27
Olson grade, need for more treatment are markers of increased skin cancer risk in actinic keratoses JournalJAMA Dermatology 6 May, 2022 00:55
Adjuvant pembrolizumab may cut recurrence, mortality in stage-II melanoma JournalThe Lancet 14 April, 2022 18:07
Is melanoma screening by primary care practitioners linked with overdiagnosis? JournalJAMA Dermatology 12 April, 2022 23:14
Merkel cell cancers recur more often than other skin cancers, usually within three years JournalJAMA Dermatology 3 March, 2022 19:35
For sentinel node-positive melanoma treatment, location matters JournalAnnals of Surgery 21 February, 2022 18:04
Race, socioeconomic status tied to melanoma survival JournalJournal of the American Academy of Dermatology 18 February, 2022 16:28
Therapeutic lymph node dissection may not be needed in melanoma when index node responds JournalJAMA Surgery 15 February, 2022 22:42
Radiomic signature may predict survival in pembrolizumab-treated advanced melanoma JournalJAMA Oncology 25 January, 2022 23:28
High-fiber diet tied to better immunotherapy response and progression-free survival in melanoma JournalScience 3 January, 2022 22:11
Patient-led surveillance safe, feasible after localized melanoma treatment JournalJAMA Dermatology 10 December, 2021 22:51
Expanding the toolbox: what is new in melanoma detection? Presented ByProf. James Grichnik, University of South Florida, USA ConferenceICD 2021 2 December, 2021 17:21
Triplet regimen boosts survival in metastatic melanoma, but at a cost JournalJAMA Network Open 26 November, 2021 23:33
Adjuvant immunotherapy reduces risk of disease recurrence in stage II melanoma Presented ByDr Jason Luke, UPMC Hillman Cancer Center, PA, USA TrialPhase 3, KEYNOTE-716 ConferenceESMO 2021 19 November, 2021 09:30
IFN-γ signature predicts response to immunotherapy Presented ByProf. Christian Blank, Netherlands Cancer Institute, the Netherlands TrialPhase 1, DONIMI ConferenceESMO 2021 19 November, 2021 09:30
Updated results of SECOMBIT trial Presented ByProf. Paolo Ascierto, Istituto Nazionale Tumori "Fondazione Pascale", Italy TrialPhase 2, SECOMBIT ConferenceESMO 2021 19 November, 2021 09:30
Combining T-VEC and pembrolizumab does not significantly improve survival in advanced, unresectable melanoma Presented ByDr Helen Gogas, National and Kapodistrian University of Athens, Greece TrialPhase 3, MASTERKEY-265 ConferenceESMO 2021 19 November, 2021 09:30
Durable intracranial responses with nivolumab/ipilimumab Presented ByDr Kim Margolin, City of Hope, CA, USA TrialPhase 2, CheckMate204 ConferenceESMO 2021 19 November, 2021 09:29
Early ctDNA reduction in metastatic uveal melanoma correlates better with OS than RECIST response Presented ByDr Alexander Shoushtari, Memorial Sloan Kettering Cancer Center, NY, USA TrialPhase 1/2, IMCgp100-202 ConferenceESMO 2021 19 November, 2021 09:09
‘Diligent’ dermatology care needed in organ-transplant recipients JournalJAMA Dermatology 22 October, 2021 22:08
ESMO 2021 Highlights Podcast Presented ByDr Rachel Giles, Medicom TrialDESTINY-Breast03, MONALEESA-2, KEYNOTE-716, CASPIAN, CheckMate-649, Impower010 ConferenceESMO 2021 4 October, 2021 09:27
Support for adjuvant pembrolizumab in earlier-stage melanoma ConferenceESMO 2021 Congress 21 September, 2021 16:18
Nodal classification system improves assessment of cutaneous melanoma mortality risk JournalJAMA Surgery 8 September, 2021 18:15
Adoptive cell therapy less effective in pretreated metastatic melanoma JournalClinical Cancer Research 24 August, 2021 16:23
First-in-class gel shows promise for basal-cell carcinoma JournalClinical Cancer Research 13 August, 2021 17:18
Long-term results from ground-breaking melanoma trials Presented ByDr Jedd Wolchok (Memorial Sloan Kettering Cancer Center, NY, USA). Prof. Reinhard Dummer (University Hospital Zürich, Switzerland) , Prof. Georgina Long (Melanoma Institute, Australia) TrialCheckMate 067, COLUMBUS, ABC ConferenceASCO 2021 12 August, 2021 23:10
Novel dual checkpoint blockade improves progression-free survival in melanoma Presented ByDr Evan Lipson, Johns Hopkins University, MD, USA TrialPhase 3, RELATIVITY-047 ConferenceASCO 2021 12 August, 2021 22:14
Neoadjuvant therapy with nivolumab plus relatlimab is safe and effective in patients with stage III melanoma Presented ByDr Rodabe Amaria , MD Anderson Cancer Center, TX, USA TrialPhase 2 ConferenceASCO 2021 12 August, 2021 12:16
Lifileucel promising against unresponsive malignant melanoma JournalJournal of Clinical Oncology 1 June, 2021 18:20
“Encouraging” data on ipilimumab plus anti-PD-1 in metastatic melanoma JournalLancet Oncology 31 May, 2021 16:51
Surveillance, education may help to catch melanomas earlier JournalCancer Epidemiology, Biomarkers and Prevention 16 April, 2021 19:01
Novel drug first to improve outcome of metastatic uveal melanoma ConferenceAmerican Association for Cancer Research (AACR) virtual annual meeting 2021 15 April, 2021 19:13
Common blood pressure medications linked to increased skin cancer risk JournalCMAJ 12 April, 2021 23:11
Survival after Mohs surgery likely better at academic, high-volume facilities JournalJAMA Dermatology 6 April, 2021 22:32
Chronic immune-related adverse events likely common after anti-PD-1 therapy for melanoma JournalJAMA Oncology 1 April, 2021 23:34
Larger surgical margins tied to better outcomes in Merkel cell carcinoma JournalJAMA Dermatology 1 April, 2021 18:49
ctDNA levels promising for tracking melanoma treatment progress, predicting outcomes JournalThe Lancet Oncology 22 February, 2021 23:33
Reassuring data on immune checkpoint inhibitors in autoimmune disease JournalAnnals of Internal Medicine 17 February, 2021 23:57
Fecal microbiota transplant in melanoma patients helps anti-PD-1 therapy work JournalScience 11 February, 2021 22:45
Personal neoantigen vaccine prompts lasting response in melanoma patients JournalNature Medicine online 5 February, 2021 17:30
UV-induced mutations in seemingly normal skin may predict skin cancer JournalScience Advances 11 January, 2021 23:28
Metastatic-melanoma immunotherapy may be tied to increase in second cancers JournalJAMA Network Open 17 December, 2020 17:34
Adjuvant immune checkpoint inhibition after complete resection ConferenceESMO 2020 25 November, 2020 14:55
Mohs surgery may not boost survival over standard excision of melanomas on trunk, extremities JournalJAMA Dermatology 29 October, 2020 17:03
Melanoma patients still at higher risk for new malignancy after successful systemic immunotherapy JournalJAMA Dermatology 24 September, 2020 18:11
Five-year follow-up confirms drug combo lowers odds of melanoma recurrence JournalNew England Journal of Medicine 2 September, 2020 23:00
Adjuvant pembrolizumab: durable RFS for stage III melanoma Presented ByProf. Alexander Eggermont, Princess Máxima Centre, NL TrialPhase 3, EORTC 1325-MG/KEYNOTE-054 ConferenceASCO 2020 28 August, 2020 15:45
Pembrolizumab plus low-dose ipilimumab well tolerated after progression on PD1 antibody therapy Principal InvestigatorDr Daniel Olson, The University of Chicago Comprehensive Cancer Center, IL, USA TrialPhase 2 ConferenceASCO 2020 28 August, 2020 15:05
Toripalimab plus axitinib effective in metastatic mucosal melanoma Presented ByDr Xinan Sheng, Peking University Cancer Hospital and Institute, China TrialPhase 1 ConferenceASCO 2020 28 August, 2020 14:13
Pembrolizumab leads to higher toxicity risk in obese melanoma patients Presented ByMs Surya Ravichandran, Duke University, USA ConferenceAAD 2020 6 August, 2020 07:03
Can gene expression help to pick the right biologic to treat psoriasis in cancer patients? Presented ByDr Nikolai Klebanov , Brigham and Women’s Hospital, USA ConferenceAAD 2020 6 August, 2020 07:01
Long-term data from CheckMate 067 Presented ByProf. James Larkin, Royal Marsden NHS Foundation Trust, London, UK TrialPhase 3, CheckMate 067 ConferenceESMO 2019 26 November, 2019 23:06
Adjuvant nivolumab provides benefit Presented ByProf. Jeffrey S. Weber, NYU Langone Medical Center, New York City, USA TrialPhase 3, CheckMate 238 ConferenceESMO 2019 26 November, 2019 22:15
Nivolumab+ipilimumab superior to monotherapy for melanoma brain metastases Presented ByProf. Georgina Long, Melanoma Institute Australia, Sydney, Australia TrialABC ConferenceESMO 2019 26 November, 2019 14:15
Above-the-neck melanoma more prone to metastases Presented ByDr Mohammed Al Abadie, Cross Hospital; Cannock Chase Hospital, United Kingdom ConferenceEADV 2019 9 October, 2019 20:53
Systemic photoprotection: a valuable addition to topical sun protection Presented ByProf. Salvador González Rodriguez, University of Alcala de Henares, Spain ConferenceEADV 2019 9 October, 2019 19:35
The underestimated effect of visible light Presented ByDr Serena Lembo, University of Naples Federico II, Italy ConferenceEADV 2019 9 October, 2019 14:38
Will malignant melanoma become a curable disease? Presented ByProf. Claus Garbe; Prof. Caroline Robert TrialCOMBI-d, COMBI-v, COMBI-i, KEYNOTE-001 ConferenceWCD 2019 26 August, 2019 20:46
Surgical management of melanoma Presented ByProf. John Kelly, The Alfred Hospital, Australia ConferenceWCD 2019 26 August, 2019 11:48
Nivolumab-mediated adverse events are independent of efficacy in resected advanced melanoma Presented ByProf. Mario Mandalà, Papa Giovanni XXIII Cancer Centre Hospital, Bergamo, Italy TrialCheckMate 238 ConferenceASCO 2019 15 July, 2019 23:18
Long term quality of life with nivolumab, or in combination (ipilimumab) in advanced melanoma TrialPhase 3, CheckMate 067 ConferenceASCO 2019 15 July, 2019 12:45
Intralesional 5-fluorouracil induced high clearance rates in cutaneous squamous cell carcinoma Presented ByDr Emma Guttman-Yassky, Mount Sinai School of Medicine, USA ConferenceAAD 2019 19 April, 2019 15:20
Melanoma incidence continues to rise in Europe Presented ByEmily Dando, University of Pittsburgh School of Medicine, USA ConferenceAAD 2018 20 December, 2018 18:15
Lesions in paediatric patients and possible correlation with coffee drinking Presented ByDr Ryan Kelm, Feinberg School of Medicine, USA ConferenceAAD 2018 20 December, 2018 17:22
CNNs and targeted combination therapy Presented ByDr Allan Halpern, Memorial Sloan Kettering Cancer Center, USA ConferenceAAD 2018 20 December, 2018 15:27